SFM
BCLI

Sphera Funds Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Sphera Funds Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-55,576
Closed -$2.76M – 133
2017
Q2 		$2.76M Buy
+55,576
New +$3.43M 0.47% 66
2014
Q4 		– Sell
-4,222
Closed -$265K – 132
2014
Q3 		$265K Buy
+4,222
New +$260K 0.03% 122

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sphera Funds Management's BCLI Position: Q3 2017 in Review

Sphera Funds Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2017, closing a stake of 55,576 shares — an estimated $2.76M sold.

Sphera Funds Management first reported a position in BCLI in Q3 2014 and held it in 2 quarters. The position peaked at $2.76M in Q2 2017. 32 funds tracked by Wall St. Rank hold BCLI as of Q3 2017.

  • Sphera Funds Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2017 after selling out during the quarter.
  • Sphera Funds Management sold 55,576 BRAINSTORM CELL THERAPUTC shares in Q3 2017, an estimated $2.76M.
  • Sphera Funds Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2014 and held it in 2 quarters.
  • Sphera Funds Management's BRAINSTORM CELL THERAPUTC position peaked at $2.76M in Q2 2017.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2017.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.